|
1
|
Rubnitz JE, Gibson B and Smith FO: Acute
myeloid leukemia (Review). Pediatr Clin North Am. 55:21–51. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Nully Brown P, Jurlander J,
Pedersen-Bjergaard J, et al: The prognostic significance of
chromosomal analysis and immunophenotyping in 117 patients with
de novo acute myeloid leukemia. Leuk Res. 21:985–995. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tian Y, Huang Z, Wang Z, et al:
Identification of novel molecular markers for prognosis estimation
of acute myeloid leukemia: Over-expression of PDCD7, FIS1 and Ang2
may indicate poor prognosis in pretreatment patients with acute
myeloid leukemia. PLoS One. 9:e841502014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Damm F, Heuser M, Morgan M, et al:
Integrative prognostic risk score in acute myeloid leukemia with
normal karyotype. Blood. 117:4561–4568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heasma SA, Zaiseva L, Bowles KM, et al:
Protection of acute myeloid leukemia cells from apoptosis induced
by front-line chemotherapeutics is mediated by haem oxyenase-1.
Oncotarget. 2:658–668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu RP, Hayashi T, Cottam HB, Jin G, Yao S,
Wu CC, Rosenbach MD, Corr M, Schwab RB and Carson DA: Nrf2
responses and the theraputic selectivity of electrophilic compounds
in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A.
107:7479–7484. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nishiya T, Kataoka H, Mori K, Goto M,
Sugawara T and Furuhama K: Tienilic acid enhances
hyperbilirubinemia in Eisai hyperbilirubinuria rats through hepatic
multidrug resistance-associated protein 3 and heme oxygenase-1
induction. Toxicol Sci. 91:651–659. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hileman EO, Liu J, Albitar M, Keating MJ
and Huang P: Intrinsic oxidative stress in cancer cells: A
biochemical basis for therapeutic selectivity. Cancer Chemother
Pharmacol. 53:209–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fang J, Sawa T, Akaike T, Greish K and
Maeda H: Enhancement of cheotherapeutic response of tumor cells by
a heme oxygenase inhibitor, pegylated znic protoporphyrin. Int J
Cancer. 109:1–8. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zou M, Baitei EY, Alzahrani AS, BinHumaid
FS, Alkhafaji D, Al-Rijjal RA, Meyer BF and Shi Y: Concomitant RAS,
RET/PTC, or BRAF mutations in advanced stage of papillary thyroid
carcinoma. Thyroid. 24:1255–1266. 2014. View Article : Google Scholar
|
|
11
|
Zhang F, Tang JM, Wang L, Wu PP and Zhang
M: Immunohistochemical detection of RET proto-oncogene product in
tumoral and nontumoral mucosae of gastric cancer. Anal Quant
Cytopathol Histpathol. 36:128–136. 2014.PubMed/NCBI
|
|
12
|
Gattei V, Degan M, Aldinucci D, De Iuliis
A, Rossi FM, Mazzocco FT, Rupolo M, Zagonel V and Pinto A:
Differential expression of the RET gene in human acute myeloid
leukemia. Ann Hematol. 77:207–210. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang ZG, Delva L, Gaboli M, Rivi R,
Giorgio M, Cordon-Cardo C, Grosveld F and Pandolfi PP: Role of PML
in cell grow and the retinoic acid pathway. Science. 279:1547–1551.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gambaeorta M, Flenghi L, Fagioli M, Pileri
S, Leoncini L, Bigerna B, Pacini R, Tanci LN, Pasqualucci L, Ascani
S, et al: Heterogeneous nuclear expression of the promyelocytic
leukemia (PML) protein in normal and neoplastic human tissues. Am
Pathol. 149:2023–2035. 1996.
|
|
15
|
Gurrieri C, Capodieci P, Bernardi R,
Scaglioni PP, Nafa K, Rush LJ, Verbel DA, Cordon-Cardo C and
Pandolfi PP: Loss of the tumor suppressor PML in human cancers of
multiple histologic origins. J NatL Cancer Inst. 96:269–279. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koken M, Linare-Cruz G, Quignon F, Viron
A, Chelbi-Alix MK, Sobczak-Thépot J, Juhlin L, Degos L, Calvo F and
de Thé H: The PML growth-suppressior has altered expression in
human oncogenesis. Oncogene. 10:1315–1324. 1995.PubMed/NCBI
|
|
17
|
Cao TY, Duprez E, Borden KL, Freemont PS
and Etkin LD: Ret finger protein is a normal component of PML
nuclear bodies and interacts directly wity PML. J Cell Sci.
111:1319–1329. 1998.PubMed/NCBI
|
|
18
|
Slovak ML, Kopecky KJ, Cassileth PA,
Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR,
Rowe JM, et al: Karyotypic analysis predicts outcome of
preremission and postremission therapy in adult acute myeloid
leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology
Group study. Blood. 96:4075–4083. 2000.PubMed/NCBI
|
|
19
|
O'Donnell MR, Abboud CN, Altman J, et al:
Acute myeloid leukemia. J Natl Compr Cancer Netw. 10:984–1021.
2012.
|
|
20
|
Döhner H, Estey EH, Amadori S, et al:
Diagnosis and management of acute myeloid leukemia in adults:
Recommendations from an international expert panel, on behalf of
the European Leukemia Net. Blood. 115:453–474. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sanchez M, Levine RL and Rampal R:
Integrating genomics into prognostic models for AML. Semin Hematol.
51:298–305. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Juliusson G, Antunovic P, Derolf A, et al:
Age and acute myeloid leukemia: Real world data on decision to
treat and outcomes from the Swedish acute leukemia registry. Blood.
113:4179–4187. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Berberat PO, Dambrauskas Z, Gulbinas A,
Giese T, Giese N, Künzli B, Autschbach F, Meuer S, Büchler MW and
Friess H: Inhibition of heme oxygenase-1 increase responsiveness of
pancreatic cancer cells to anticancer treatment. Clin Cancer Res.
11:3790–3798. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mcalliister SC, Hansen SG, Ruhl RA, Raggo
CM, DeFilippis VR, Greenspan D, Früh K and Moses AV: Kaposi
sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1
expression and activity in KSHV-infected endothelial cells. Blood.
103:3465–3473. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Was H, Dulak J and Jozkowica A: Heme
Oxygenase-1 in tumor biology and therapy. Curr Drug Targets.
11:1551–1570. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miyazaki T, Kirino Y, Takeno M, Samukawa
S, Hama M, Tanaka M, Yamaji S, Ueda A, Tomita N, Fujita H and
Ishigatsubo Y: Expression of heme oxygenase-1 in human leukemia
cells and its regulation by transcriptional repressor Bach1. Cancer
Sci. 101:1409–1416. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rushworth SA and MacEwan DJ: HO-1
underlies resistance of AML cells to TNF-induced apoptosis. Blood.
111:3793–3801. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mayerhofer M, Florian S, Krauth MT,
Aichberger KJ, Bilban M, Marculescu R, Printz D, Fritsch G, Wagner
O and Selzer E: Identification of heme oxygenase-1 as a novel
BCR/ABL-dependent survival factor in chronic myeloid leukemia.
Cancer Res. 64:3148–3154. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jensen K, Shiels C and Freemont PS: PML
protein isoforms and the RBCC/TRIM motif. Oncogene. 20:7223–7233.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rego EM, Wang ZG, Peruzzi D, He LZ,
Cordon-Cardo C and Pandolfi PP: Role of promyelocytic leukemia
(PML) protein in tumor suppression. J Exp Med. 193:521–529. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Szendefi M, Walt H, Krasieva TB, Caduff R,
Osann KE and LaMorte VJ: Association between promyelocyte protein
and smallubiquitin-like modifier protein and the progression of
cervical neoplasia. Obstet Gynecol. 102:1269–1277. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mu ZM, Chin KV, Liu JH, Lozano G and Chang
KS: PML a growth suppressor disrupted in acute promyelocytic
leukemia. Mol Cell Biol. 14:6858–6867. 1994.PubMed/NCBI
|
|
33
|
Liu JH, Mu ZM and Chang KS: PML suppresses
oncogenic-transformation of NIH 3T3 cells by activated neu. J Exp
Med. 181:1965–1973. 1995. View Article : Google Scholar : PubMed/NCBI
|
